NCT02152254: IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer

NCT02152254
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Chemotherapy, Endocrine (Hormone) Therapy, Immunotherapy, Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://clinicaltrials.gov/show/NCT02152254

Comments are closed.

Up ↑